Linomide
(Redirected from
Roquinimex
) | |
| Clinical data | |
|---|---|
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 26-42 hours |
| Identifiers | |
| |
JSmol) | |
| |
| |
  (what is this?) (verify) | |
Linomide (Roquinimex) is a
TNF alpha
.
Linomide has been investigated as a treatment for some cancers (including as adjuvant therapy after
type I diabetes.[3]
Several trials have been terminated due to serious cardiovascular toxicity.
Synthesis
Ethyl 2-(methylamino)benzoate is condensed with
N-methylaniline
results in formation of the amide linomide.
References
- S2CID 31845910.
- PMID 11407306.
- PMID 11407307.
- ^ EP 59698, Eriksoo, Edgar; Sandberg, Eva Britt-Marie & Stalhandsk, Lars Johan Torbjörn, "Heterocyclic carboxamides, compositions containing such compounds, processes for their preparation and methods of treatment therewith", published 1982-09-08, assigned to AB Leo; E. Eriksoo et al., U.S. patent 4,738,971 (1988 to AB Leo).